JP2008543767A5 - - Google Patents

Download PDF

Info

Publication number
JP2008543767A5
JP2008543767A5 JP2008515929A JP2008515929A JP2008543767A5 JP 2008543767 A5 JP2008543767 A5 JP 2008543767A5 JP 2008515929 A JP2008515929 A JP 2008515929A JP 2008515929 A JP2008515929 A JP 2008515929A JP 2008543767 A5 JP2008543767 A5 JP 2008543767A5
Authority
JP
Japan
Prior art keywords
tablet
lubricant
lubricants
tablets
mixing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008515929A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008543767A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/022336 external-priority patent/WO2006135693A2/en
Publication of JP2008543767A publication Critical patent/JP2008543767A/ja
Publication of JP2008543767A5 publication Critical patent/JP2008543767A5/ja
Pending legal-status Critical Current

Links

JP2008515929A 2005-06-10 2006-06-08 Ｄｐｐ−ｉｖ阻害剤とグリタゾンの直接圧縮製剤および方法 Pending JP2008543767A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68973905P 2005-06-10 2005-06-10
US69052705P 2005-06-14 2005-06-14
US69081405P 2005-06-15 2005-06-15
PCT/US2006/022336 WO2006135693A2 (en) 2005-06-10 2006-06-08 Direct compression formulation of dpp-iv inhibitors and glitazones, and process

Publications (2)

Publication Number Publication Date
JP2008543767A JP2008543767A (ja) 2008-12-04
JP2008543767A5 true JP2008543767A5 (2) 2009-07-02

Family

ID=37198127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008515929A Pending JP2008543767A (ja) 2005-06-10 2006-06-08 Ｄｐｐ−ｉｖ阻害剤とグリタゾンの直接圧縮製剤および方法

Country Status (14)

Country Link
US (1) US20080193529A1 (2)
EP (1) EP1893236A2 (2)
JP (1) JP2008543767A (2)
KR (1) KR20080018257A (2)
AR (1) AR054382A1 (2)
AU (2) AU2006258013A1 (2)
BR (1) BRPI0613567A2 (2)
CA (1) CA2610412A1 (2)
GT (1) GT200600218A (2)
MX (1) MX2007015612A (2)
PE (1) PE20070165A1 (2)
SA (1) SA06270158B1 (2)
TW (1) TW200716175A (2)
WO (1) WO2006135693A2 (2)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
SG10201809313WA (en) * 2005-09-29 2018-11-29 Novartis Ag Formulation comprising metformin and vildagli ptin
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
MY147596A (en) 2007-02-01 2012-12-31 Takeda Pharmaceutical Solid preparation comprising alogliptin and pioglitazone
PE20090597A1 (es) * 2007-08-16 2009-06-06 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
AU2014262269B2 (en) * 2008-04-03 2017-02-02 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101054911B1 (ko) 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
PL2395983T3 (pl) 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
SI2459531T1 (sl) * 2009-07-31 2020-02-28 Krka, D.D., Novo Mesto Granulat, ki obsega vildagliptin, in postopek njegove priprave
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
JP5826830B2 (ja) * 2010-05-05 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピオグリタゾンとリナグリプチンを含む医薬製剤
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
CN102657626B (zh) * 2012-05-23 2013-07-17 重庆康刻尔制药有限公司 一种盐酸吡格列酮药物组合片剂
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014193528A1 (en) * 2013-04-29 2014-12-04 Anovel Pharmaceuticals, Llc Amorphous dosage forms and methods
WO2015012365A1 (ja) * 2013-07-25 2015-01-29 株式会社 三和化学研究所 医薬製剤
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
JP7379189B2 (ja) * 2020-01-31 2023-11-14 沢井製薬株式会社 ビルダグリプチン含有コーティング粒子、ビルダグリプチン含有口腔内崩壊錠、ビルダグリプチン含有コーティング粒子の製造方法及びビルダグリプチン含有口腔内崩壊錠の製造方法
TR202010700A2 (tr) * 2020-07-06 2022-01-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vi̇ldagli̇pti̇n ve en az bi̇r farmasöti̇k olarak kabul edi̇lebi̇li̇r eksi̇pi̇yan i̇çeren bi̇r formülasyon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
DK1248604T4 (da) * 2000-01-21 2012-05-21 Novartis Ag Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7510728B2 (en) * 2000-10-06 2009-03-31 Takeda Pharmaceutical Company Limited Solid preparations
US6573287B2 (en) * 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
US20040186046A1 (en) * 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
EP1671649B1 (en) * 2003-10-03 2011-11-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase IV inhibitors for treating diabetic patients with sulfonylurea secondary failure
EP1807066A1 (en) * 2004-10-25 2007-07-18 Novartis AG Combination of dpp-iv inhibitor, ppar antidiabetic and metformin

Similar Documents

Publication Publication Date Title
EP2777696B1 (en) Preparation of stable pharmaceutical dosage forms
US10828258B2 (en) Directly compressible composition comprising microcrystalline cellulose
DK3174530T3 (en) DIRECT COMPATIBLE POLYVINYL ALCOHOLS
WO2011071139A1 (ja) 有核型の口腔内崩壊錠
US20110293717A1 (en) Compacted moxifloxacin
WO2017217494A1 (ja) 口腔内崩壊錠
JP2016104812A (ja) ロキソプロフェンナトリウム及びトラネキサム酸を含有する固形製剤
KR20120098878A (ko) 용출 안정성 제제
GB2444904A (en) A process for the preparation of an orally administered unit dose tablet
JP7652778B2 (ja) 錠剤およびその製造方法
JP6106359B2 (ja) ロキソプロフェンナトリウムとビタミンｂ１を含有する固形製剤
JP6114573B2 (ja) ロキソプロフェンナトリウムと制酸剤を含有する固形製剤
JP5900702B2 (ja) 経口投与用医薬組成物
JP4573542B2 (ja) ビタミンｂ１誘導体組成物
JP6112765B2 (ja) ロキソプロフェンナトリウム及びｄｌ−メチルエフェドリン塩酸塩を含有する固形製剤
JP6037687B2 (ja) グリメピリドを含有する口腔内崩壊錠
Kolli et al. Formulation and evaluation of matrix tablet of ramipril
EP2554164A1 (en) Pharmaceutical formulation based on ibuprofen and codeine having having improved stability
JP2025115147A (ja) エドキサバンを含む医薬組成物の製造方法、及びエドキサバンを含む医薬組成物からのエドキサバンの溶出性の改善方法
JP2025101742A (ja) セレキシパグ含有医薬
JP2024531701A (ja) ベムペド酸医薬組成物
Raju et al. Preparation and characterization of bi-layer matrix tablets of amoxicillin tri-hydrate
JP2005015363A (ja) 小型化クラリスロマイシン錠剤
IES84888Y1 (en) A process for the preparation of an orally administered unit dose tablet
JP2015057434A (ja) 医薬品又は食品用の粉体圧縮成形物、及びその製造方法